drugset
drugset / Trial / NCT02259907

Safety, Tolerability and Pharmacokinetics of KUC 7483 Tablets in Healthy Male Volunteers

NCT02259907 ↗

Phase 1 Completed 50 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate safety, tolerability and pharmacokinetics of KUC 7483

Timeline

Start
2003-05
Primary completion
2004-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritobegron Small molecule 40 mg Oral
Subject Ritobegron Small molecule 80 mg Oral
Subject Ritobegron Small molecule 400 mg Oral

Indications

No indication recorded.